But this is just the start. GLP-1 drugs (specifically Novo Nordisk’s Ozempic, Rybelsus and Wegovy and Eli Lilly’s Mounjaro ...

Novo Nordisk has invested 6.4bn Brazilian reais ($1.09bn) to expand its facility in Brazil as the company ramps up efforts to ...

While much of the recent GLP-1 saga has been written in the U.S., Novo Nordisk continues to expand its semaglutide empire ...

Novo Nordisk invests $1.05B in Brazil factory to boost GLP-1 drug production, including Wegovy and Ozempic, creating 600 jobs ...

Novo Nordisk, the producer of Ozempic, Wegovy and other medications, will invest 6.4 billion reais ($1.09 billion) in Brazil ...

Novo Nordisk (NVO) stock dropped on Monday despite the drugmaker reporting positive results for its GLP-1 medicine, Rybelsus.

As demand soared for weight-loss drugs, price signals worked.

Danish pharma major Novo Nordisk has announced an investment of $1.1 billion to expand its production facility in Brazil’s ...

Current observations and foresight into the world of biosimilars, GLP-1s, PBM and payer trends, according to Jeff Casberg, MS ...

Novo Nordisk ) is going big in Brazil. The drugmaker behind Ozempic and Wegovy just dropped a $1.09 billion investment to ...

The Danish pharmaceutical company behind obesity drug Wegovy, Novo Nordisk, plans to invest US$1.09bn in expanding its ...

Novo Nordisk (NVO), the company behind Ozempic and Wegovy, announced that it will invest 6.4 billion reais (about $1.09 ...